Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728448 | 0.83 | CTSL (0.45) | CTSLCTSBCTSKBUB1TAAR1 | |
| SCHEMBL23744430 | 0.83 | CTSL (0.45) | CTSLCTSBCTSKBUB1TAAR1 | |
| SCHEMBL28840618 | 0.79 | ALDH1A1 (0.43) | CTSLCTSBCTSKAGTR2TSHR | |
| SCHEMBL6649338 | 0.79 | TSHR (0.54) | CTSLCTSBCTSKTAAR1TSHR | |
| SCHEMBL7280676 | 0.79 | CTSL (0.46) | CTSLCTSBCTSKAGTR2TAAR1 | |
| SCHEMBL27196374 | 0.79 | CTSL (0.46) | CTSLCTSBCTSKAGTR2TAAR1 | |
| SCHEMBL7279522 | 0.79 | CTSL (0.46) | CTSLCTSBCTSKAGTR2TSHR | |
| SCHEMBL4677170 | 0.76 | TSHR (0.54) | CTSLCTSBCTSKTAAR1TSHR | |
| SCHEMBL403013 | 0.74 | CTSL (0.45) | CTSLCTSBCTSKAGTR2TSHR | |
| SCHEMBL2701945 | 0.74 | CTSL (0.53) | CTSLCTSBCTSKTAAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CTSL 941/4885CTSB 527/4885CTSK 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.